an innovator in the high-throughput discovery, characterisation, and development of human-derived antibodies
Mabylon has raised €32M across 1 funding round from 1 investor, most recently a round in Aug 2025. Based in Zurich, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-08-12 | Other | €32M |
| existing private investors |
| View deal → |
